SelSym Biotech is an early-stage biotech startup focused on revolutionizing bleeding management and wound care through the development of synthetic platelet technologies. SelSym's lead product, SymClot, is a synthetic platelet capable of addressing unmet needs in hemorrhage in both trauma and surgery. SelSym is co-founded by academic inventors at North Carolina State University, Georgia Tech, and the University of Virginia and began translational development on its SymClot product in 2021